IL2 and cancer: Additional examples of dual-cytokine fusions described in the literature and tested in preclinical cancer models include those based on anti-CD30 + IL2/IL12, anti-CD38 + IL2/TRAIL, and anti-HER2 + IL12/IL2 or GM-CSF [24,25,26,27].